Advances in CRISPR technologies promise to accelerate the burgeoning pipeline of gene-editing therapies and broaden access to these disease-altering therapies.

Australian cancer researchers are the first to establish a next-generation gene-editing tool for modeling and interrogating ...

This new tool, known as minimal, versatile genetic perturbation technology (mvGPT), combines the powers of gene editing, ...

Australian researchers have successfully introduced an improved version of Cas12a gene-editing enzyme in mice.

Australian cancer researchers are the first to establish a next-generation gene-editing tool for modelling and interrogating human disease.

Fintel reports that on January 27, 2025, Morgan Stanley downgraded their outlook for Intellia Therapeutics (NasdaqGM:NTLA) from Overweight to Equal-Weight. Analyst Price Forecast Suggests 449.14% ...

Australian cancer researchers are the first to establish a next-generation gene-editing tool for modeling and interrogating human disease.

Intellia Therapeutics has dosed the first subject in the Phase III trial of NTLA-2002, to treat hereditary angioedema (HAE).

Results prove that inversions can be generated in plants without causing further unwanted changes in the expression of genetic information.

Mammoth Biosciences, Inc., a biotechnology company harnessing its proprietary next-generation CRISPR gene editing platform to create potential one-time curative therapies, today announced new ...

Innovative synthetic biology techniques are revolutionizing microbiota-based therapies, enhancing microbial functions for ...

Australian cancer researchers are the first to establish a next-generation gene-editing tool for modelling and interrogating human disease.A novel ...